Literature DB >> 31217146

Usefulness of mean pulmonary artery pressure for predicting outcomes of transcatheter closure of atrial septal defect with pulmonary arterial hypertension.

Wenzhi Pan1, Yuan Zhang, Lihua Guan, Xiaochun Zhang, Lei Zhang, Lifan Yang, Junbo Ge, Daxin Zhou.   

Abstract

AIMS: This study aimed to provide a simple index for predicting the definitive indication for transcatheter closure of atrial septal defect (ASD) with pulmonary arterial hypertension (PAH). METHODS AND
RESULTS: A positive response after attempted occlusion was defined as mean pulmonary artery pressure (MPAP) ≤30 mmHg or the decrement percentage of it ≥20% compared with baseline. If a positive response was achieved, the occluder would be released, and the procedure was defined as successful. In 209 patients who underwent a successful procedure without PAH-specific medicine, there was a dramatic decrease in the percentage of patients with pulmonary arterial systolic pressure (PASP) ≥50 mmHg from baseline to the one-year follow-up (79.4% to 14.0%, p<0.001). The optimal cut-off value of MPAP to predict a positive response without PAH-specific medicine was 35.0 mmHg, with an area under the curve (AUC) of 0.919 (p<0.001). Administration of inhaled iloprost extended the cut-off point to 50.0 mmHg to reach a positive response, with an AUC of 0.774 (p=0.003).
CONCLUSIONS: This large-scale study indicated that MPAP could be a simple but powerful index to predict benefit from closure in adult ASD patients with PAH.

Entities:  

Year:  2020        PMID: 31217146     DOI: 10.4244/EIJ-D-19-00172

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  1 in total

1.  Case report: The impact of percutaneous atrial septal defect closure in pulmonary hypertension with co-existing cor triatriatum sinister and multiple cardiac comorbidities.

Authors:  I-Hsin Tai; Tsung-Cheng Shyu; Kai-Sheng Hsieh; Ke-Wei Chen; Wan-Jane Tsai; Kuo-Yang Wang
Journal:  Front Cardiovasc Med       Date:  2022-09-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.